Advertisement

Topics

Search Results for "Metformin Hidradenitis"

14:43 EST 22nd February 2017 | BioPortfolio

Matching Channels

Matching News

U.S. FDA Approves INVOKAMET® XR (Canagliflozin / Metformin Hydrochloride Extended-Release) for ...

Phase 3 studies have shown the combination of INVOKANA ®and metformin reduces A1C significantly more than metformin alone, sitagliptin plus metformin, or glimepiride plus Read more...

Elcelyx's Metformin DR meets Phase IIb diabetes endpoint

Elcelyx Therapeutics Inc. (San Diego, Calif.) said Metformin DR met the primary endpoint in a Phase IIb trial to treat Type II diabetes. The delayed-release, enteric-coated tablet formulation of metfo...

Metformin use linked to less vitamin B12 measurement

(HealthDay)—Long-term metformin use is associated with lower serum vitamin B12 concentration, although metformin users are less likely to receive vitamin B12 testing, according to a study published ...

Metformin influences nitrogen and urea metabolism

The most frequently prescribed oral antidiabetic drug metformin significantly affects metabolic pathways, report scientists. Metformin is a widespread oral medication to increase insulin sensitivity i...

Metformin may reduce mortality in patients with certain chronic diseases

Recent changes in metformin labeling by the FDA is supported by new findings published in Annals of Internal Medicine that suggest that patients with chronic kidney disease, congestive heart failure a...

Elcelyx Therapeutics reports positive Phase IIb study results of Metformin DR to treat type 2 diabetes

Elcelyx Therapeutics has reported that its Phase 2b dose-ranging study met the primary endpoint of indicating a statistically significant reduction in HbA1c at 16 weeks with Metformin Delayed Release ...

Elcelyx unveils positive results in phase 2b study of Metformin DR in type 2 diabetes

Elcelyx Therapeutics announced today that its Phase 2b doseranging study met the primary endpoint of showing a statistically significant reduction in HbA1c at 16 weeks with Metformin Delayed Release (...

Extended EU treatment access for metformin products

The European Commission (EC) has authorized the extension of the label for all metformin-containing products…

Matching PubMed Articles

Hidradenitis suppurativa (HS) and Down syndrome (DS): Increased prevalence and a younger age of hidradenitis symptom onset.

Prevalence and predictors of metformin prescribing in adults with type 2 diabetes mellitus: a national cross sectional study.

Metformin is the first-line oral type 2 diabetes treatment. Despite an abundance of evidence, metformin is routinely under-utilized. This study evaluated the rates of metformin usage in an approp...

Involvement of Glucagon-like Peptide-1 in the Glucose-lowering effect of Metformin.

Metformin is an oral antihyperglycaemic drug used as first-line treatment of type 2 diabetes. Metformin's classical and most well-known blood glucose-lowering mechanisms include reduction of hepatic g...

Understanding and overcoming metformin gastrointestinal intolerance.

Metformin is the most widely prescribed drug for patients with type 2 diabetes mellitus and the first-line pharmacologic option as supported by multiple international guidelines, yet a rather large pr...

The relationship between metformin and serum prostate-specific antigen levels.

Metformin is the first-line oral antihyperglycemic of choice for individuals with type 2 diabetes. Recent evidence supports a role for metformin in prostate cancer chemoprotection. However, whether me...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement